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Abstract
Mitochondrial translation, essential for synthesis of the electron transport chain complexes in the mitochondria, is governed
by nuclear encoded genes. Polymorphisms within these genes are increasingly being implicated in disease and may also
trigger adverse drug reactions. Statins, a class of HMG-CoA reductase inhibitors used to treat hypercholesterolemia, are
among the most widely prescribed drugs in the world. However, a significant proportion of users suffer side effects of
varying severity that commonly affect skeletal muscle. The mitochondria are one of the molecular targets of statins, and
these drugs have been known to uncover otherwise silent mitochondrial mutations. Based on yeast genetic studies, we
identify the mitochondrial translation factor MEF2 as a mediator of atorvastatin toxicity. The human ortholog of MEF2 is the
Elongation Factor Gene (EF-G) 2, which has previously been shown to play a specific role in mitochondrial ribosome
recycling. Using small interfering RNA (siRNA) silencing of expression in human cell lines, we demonstrate that the EF-G2mt
gene is required for cell growth on galactose medium, signifying an essential role for this gene in aerobic respiration.
Furthermore, EF-G2mt silenced cell lines have increased susceptibility to cell death in the presence of atorvastatin. Using
yeast as a model, conserved amino acid variants, which arise from non-synonymous single nucleotide polymorphisms
(SNPs) in the EF-G2mt gene, were generated in the yeast MEF2 gene. Although these mutations do not produce an obvious
growth phenotype, three mutations reveal an atorvastatin-sensitive phenotype and further analysis uncovers a decreased
respiratory capacity. These findings constitute the first reported phenotype associated with SNPs in the EF-G2mt gene and
implicate the human EF-G2mt gene as a pharmacogenetic candidate gene for statin toxicity in humans.
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Introduction
The primary function of the mitochondria is the aerobic
production of ATP, a process that is reliant on a series of protein
complexes that comprise the electron transport chain. Several
components of the electron transport chain are encoded in the
mitochondrial genome, the translation of which is governed largely
by nuclear encoded genes. Increasingly, mutations within these
genes are being implicated with respiratory deficiency, an
underlying factor in a number of diseases, including myopathies
and liver failure [1,2,3,4]. For example, pathogenic mutations in
the human mitochondrial elongation factor genes, EF-G1mt and
EF-Tu(mt), have been implicated with severe lactic acidosis and
encephalopathy [1,2,3]. Recently a mutation in a novel gene,
believed to be a member of the class of mitochondrial peptide
release factors, was identified in patients exhibiting symptoms of
Leigh syndrome [4].
In addition to disease, there is also emerging evidence that
respiratory deficiencies are responsible for adverse drug reactions.
Consequently, treatment with certain drugs have uncovered
otherwise silent mitochondrial mutations [5,6]. The group of
cholesterol-lowering drugs, statins, are one example. The primary
target of statins is 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase, the rate limiting enzyme of the sterol
synthesis pathway, but increasingly, studies are reporting signs of
statin-induced mitochondrial dysfunction [7,8]. This is believed to
be a factor in the myopathic side-effects of statins. Approximately
0.1 to 0.5 percent of statin users experience severe myopathic
symptoms (defined as serum creatine kinase levels more than 10
times the upper limit of normal) and many more suffer milder
musculoskeletal pain [9,10]. Frequently such patients present
symptoms that are similar to those of patients with mitochondrial
myopathies [11]. To date, there have been several case studies
reporting the presence of a subclinical MELAS (mitochondrial
encephalopathy, lactic acidosis and stroke-like episodes) mutation
within the mitochondrial DNA (mtDNA) of patients who have
developed severe myopathic symptoms following statin medication
[12,13,14]. It is expected that existing weakness in mitochondrial
PLoS Genetics | www.plosgenetics.org 1 June 2012 | Volume 8 | Issue 6 | e1002755function can be exacerbated upon exposure to statin, leading to
the uncovering of previously asymptomatic mutations in mito-
chondrial genes.
The yeast Saccharomyces cerevisiae has been the model of choice for
studies of mitochondrial function. In addition to mitochondrial
similarities with human cells, the ability of yeast to survive in the
absence of mtDNA, the simplicity with which both nuclear and
mtDNA can be manipulated and the extensive number of tools
and resources available specifically for yeast research has greatly
contributed to an understanding of potentially pathogenic
mutations [15,16,17]. Statins were first isolated as secondary
metabolites from fungi, the presumption being that the strong
antifungal properties of statins provide an ecological advantage for
the producer over other fungi, similar to that of antibiotics. We
and others have demonstrated that upon exposure to statin, yeast,
as well as having reduced cell viability, also display evidence of
mitochondrial dysfunction [18,19,20].
In this study, we identify a nuclear gene encoding a
mitochondrial translation factor as a modulator of atorvastatin
toxicity in yeast (MEF2) and human cell lines (EF-G2mt). The
eukaryotic mitochondrial protein synthesis system consists of four
phases; initiation, elongation, termination and ribosome recycling,
each carefully orchestrated by a series of nuclear encoded proteins
[21,22]. The human EF-G2mt gene, originally named a mito-
chondrial elongation factor based on sequence homology with
bacterial EF-G, has since been shown to function as a ribosome
recycling factor [23,24]. EF-G2mt is believed to interact with the
already known ribosome recycling factor (RRF1) to promote
dissociation of the ribosomal subunits following termination of
translation [23]. In bacteria, the dual role of translocation and
ribosome recycling are shared by a single EF-G protein [25].
Eukaryotic cells harbour two EF-G proteins in their mitochondria
and it appears that these have distinct functions, the EF-G1mt
protein for translocation and the EF-G2mt protein for ribosome
recycling [23,26]. The human EF-G2mt protein is conserved
across the majority of eukaryotic species [23]. With its yeast Mef2p
counterpart, the human EF-G2mt protein shares greater than 32
percent homology and four of the five protein domains. We use
the atorvastatin-sensitive phenotype of the yeast MEF2 gene to
uncover naturally occurring human variants of EF-G2mt that have
respiratory deficient phenotypes. These findings have ramifica-
tions for patient drug response and possibly also for disease.
Results
Identification of the yeast MEF2 gene as a cell mediator
of atorvastatin toxicity
In light of the emerging evidence that mitochondria are
important in dictating statin toxicity, which in turn can reveal
underlying respiratory defects that have important health impli-
cations, experiments were designed to discover mitochondrial
lesions that affect statin sensitivity. Two published fitness profiling
experiments in yeast have observed statin sensitivity in hundreds of
heterozygous deletion mutants following statin exposure for 20
generations of growth [27,28]. Using the Gene Ontology term
finder available on the Saccharomyces genome database website
(www.yeastgenome.org), we discovered approximately 14–17% of
genes conferring statin-sensitivity are associated with the mito-
chondria. One of the most sensitive of these mitochondrial
associated genes was the MEF2 gene, encoding a mitochondrial
translation factor believed to have a role in ribosome recycling
[23,27].
The growth of deletion mutants in a competition style assay is a
very sensitive method of detecting differences in growth rate.
However, these assays are prone to a higher incidence of false
positive and non-replicable results [29]. To confirm the MEF2
phenotype, a number of yeast deletion mutants that ranked as the
most statin sensitive in the fitness profiling experiments were
compared [27,28]. Both heterozygous and haploid mutants were
tested and cell viability was assessed after five days exposure to
110 mM atorvastatin. The concentration of 110 mM atorvastatin is
approximate to those concentrations used in the original genome-
wide fitness profiling screens (62.5 mM and 125 mM atorvastatin)
[27]. Furthermore, during a previous investigation of the effects of
different atorvastatin concentrations in yeast, we have shown that
110 mM atorvastatin does not inhibit cell growth but is sufficient to
cause a significant decrease in intracellular ergosterol (approxi-
mately 85%), accompanied by loss of cell viability after prolonged
exposure (5 days) [18]. Of the heterozygous mutants tested, only
the hmg1D/HMG 1 strain was confirmed to be sensitive to
atorvastatin (Figure 1A). However, of the haploid mutants tested,
three displayed a statin hypersensitive phenotype (Figure 1B). The
mef2D mutant emerged as the strain which exhibited the greatest
loss of cell viability in the presence of atorvastatin, with an almost
20-fold reduction in cell viability compared with the wild-type.
The hmg1D strain displayed a 5-fold reduction in cell viability and
disruption of the HTZ1 gene, encoding a histone protein, resulted
in a 2-fold loss of cell viability (Figure 1B).
Yeast mutants defective in mitochondrial translation undergo
rapid loss of mtDNA and we have previously shown this to be the
case for the mef2D mutant [30]. Consequently, mef2D is r
0
(completely devoid of mtDNA). To determine whether atorvasta-
tin-sensitivity is the consequence of abrogation of the MEF2 gene
or simply from the absence of mtDNA, mef2D statin sensitivity was
compared with that of ethidium bromide generated cytoplasmic r
0
mutants. In order to ensure that there were no secondary site
mutations in the mef2D deletion mutant that originated from the S.
cerevisiae gene deletion collection, new mef2D haploid strains were
created. Results show that although the r
0 strains were more
sensitive to atorvastatin than the respiratory positive parent, they
did not display the same degree of sensitivity as mef2D (Table 1).
Author Summary
The mitochondria are responsible for producing the cell’s
energy. Energy production is the result of carefully
orchestrated interactions between proteins encoded by
the mitochondrial DNA and by nuclear DNA. Sequence
variations in genes encoding these proteins have been
shown to cause disease and adverse drug reactions in
patients. The cholesterol-lowering drugs statins are one
class of drugs that interfere with mitochondrial function.
Statins are one of the most prescribed drugs in the
western world, but many users suffer side effects,
commonly muscle pain. In severe cases this can lead to
muscle breakdown and liver failure. In this study, we
discover that disruption of a mitochondrial translation
gene, EF-G2mt, impedes respiration and increases cell
death when exposed to statin. Using the simple unicellular
organism yeast as a model, the activity of naturally
occurring human EF-G2mt variants is tested. Three of
these variants render yeast cells more sensitive to statin.
Patients who possess these EF-G2mt variations may be
more susceptible to statin side effects. Importantly, the
test for statin sensitivity also led to the discovery of
mutants that have a reduced energy production capacity.
The decreased ability to produce energy is linked to a
number of diseases, including myopathies and liver failure.
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statin sensitivity through mtDNA dependent and independent
functions.
Silencing of the human EF-G2mt gene compromises
OXPHOS and exacerbates atorvastatin toxicity in human
cell lines
The human EF-G2mt gene, ortholog of the yeast MEF2 gene,
encodes a recently characterised mitochondrial ribosome recycling
factor [23], but to date, no functional analysis has been performed
for this gene. To determine whether the EF-G2mt gene is essential
for human cell function and to ascertain whether depletion
influences statin toxicity, an siRNA pool comprising of four
individual EF-G2mt targeted siRNAs was used to silence EF-G2mt
expression in the human rhabdomyosarcoma (RD) cell line. The
RD cell line has previously been established as a skeletal muscle
model for mitochondrial disorders and has also been used in
studies of statin toxicity [31,32,33]. At 72 hours post-transfection,
greater than 80 percent silencing was consistently achieved and
cells remained viable. Cells were then re-transfected at this time
point to enable continued depletion of EF-G2mt activity. This
strategy had previously uncovered an essential role for cell viability
for the first discovered ribosomal recycling factor gene, RRF1 [34].
However, at 72 hours post-re-transfection (six days after the initial
transfection), RD cells remained viable even though EF-G2mt
mRNA concentration had decreased by 99.9 percent. Addition-
ally, there was no decrease in mtDNA levels upon EF-G2mt
silencing as analysed using quantitative PCR (Figure S1) [35].
Although gross inhibition of mitochondrial translation in human
cell lines results in loss of cell viability [34], a more subtle
mitochondrial phenotype may be masked by the phenomenon of
the Crabtree effect whereby many human cell lines, when grown
in the presence of glucose, derive their energy almost solely by
fermentative means [36]. To circumvent this effect and force cells
to rely on mitochondrial respiration as their primary energy
source, galactose was used to replace glucose as the carbon source
[37]. Silencing of EF-G2mt led to a marked decline in the growth
of RD cells at four days post-transfection, which was maintained
for a period of seven days (Figure 2). This growth defect on
galactose medium signals an impairment in oxidative phosphor-
ylation (OXPHOS).
Based on the findings in yeast, it was predicted that decreased
EF-G2mt activity would also enhance the effects of atorvastatin
toxicity. EF-G2mt silenced RD cells were subjected to various
concentrations of atorvastatin in medium containing either
galactose or glucose as the carbon source for a period of 48 hours.
In glucose medium, there was no difference in statin sensitivity
between the EF-G2mt silenced cells and those transfected with the
non-targeting control. However, based on IC50 values (defined
here as a 50% loss of viability at 48 hours) in galactose medium,
EF-G2mt silenced cells were over 20 percent more sensitive to
atorvastatin than cells transfected with the non-targeting siRNA
pool (Table 2). These results confirm a role for the human EF-
G2mt gene in cell resistance to atorvastatin in a human skeletal
muscle cell line. Notably, a similar increase in sensitivity (17%) was
observed using the human hepatic HepG2 cell line (a model for
statin-induced liver toxicity), although it should be noted that
HepG2 cells are approximately 10 times more statin resistant than
RD cells and this elevation in atorvastatin sensitivity was not
statistically significant in these experiments (Table 2).
EF-G2mt protein variants, when created in yeast Mef2p,
increase atorvastatin toxicity
A global alignment of the amino acid sequence of the human
EF-G2mt protein (Isoform I, AAH15712.1) with the yeast Mef2
protein (CAA59392) reveals 32.1% amino acid sequence identity
(Figure 3 and Figure S2). At the commencement of this study,
there were nine published non-synonymous Single Nucleotide
Polymorphisms (SNPs) in the human EF-G2mt gene, of which five
were either conserved or semi-conserved in the yeast MEF2 gene.
Three of these variants, EF-G2mt
I627T, EF-G2mt
E594G and EF-
G2mt
K334R, are considered rare, with a heterozygosity frequency
below one percent. One of the variants, EF-G2mt
R744G, has a
Figure 1. Viability of yeast heterozygous and haploid deletion
mutants in atorvastatin after 5 days. (A) Percentage cell viability of
heterozygous deletion mutants in 110 mM atorvastatin relative to
viability in the solvent control. (B) Percentage cell viability of haploid
deletion mutants in 110 mM atorvastatin relative to viability in the
solvent control. Data represent mean 6 SEM (n=3). A one-way ANOVA,
followed by a Dunnett’s multiple comparison test, was used to compare
the mean percentage viability of the mutant strains to that of the wild-
type. *P,0.05, ***P,0.001.
doi:10.1371/journal.pgen.1002755.g001
Table 1. Percentage cell viability relative to solvent control
after 5 days exposure to 110 mM atorvastatin.
Mean % viability ± SEM
a
Wild-type 18.262.66***
mef2D 1.0260.194
r
0 8.0160.720**
aThree independent replicates were performed.
A one-way ANOVA, followed by a Dunnett’s multiple comparison test, was used
to compare the viability of the mef2D strains to that of the wild-type and r
0
strains.
**P,0.01,
***P,0.001.
doi:10.1371/journal.pgen.1002755.t001
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R774Q
allele has a heterozygosity frequency greater than 20 percent.
These five SNPs were selected for functional analysis using the
yeast MEF2 gene as a model.
For each of the five selected human EF-G2mt variants, single
nucleotide base pair substitutions were constructed directly into
the chromosomal copy of the yeast MEF2 gene to replace the
codon specific to the wild-type amino acid residue with a codon
that corresponds to the amino acid present in the human EF-
G2mt protein variants. The Mef2p variants constructed were
mef2
K769Q, mef2
R740G, mef2
I616T, mef2
D578G and mef2
K308R which
correspond to EF-G2mt
R774Q, EF-G2mt
R744G, EF-G2mt
I627T, EF-
G2mt
E594G and EF-G2mt
K334R respectively. To assess for respira-
tory competence, mef2 mutants were grown on medium containing
the non-fermentable carbon source glycerol. After 72 hours, all
five mutants were proficient in the production of colonies on both
glucose and glycerol medium. The number and size of colonies
produced by the mutant strains on glycerol medium was equal to
that of the wild-type, indicating that all mutants are respiratory
competent (Figure 4A). Moreover, based on measurements of cell
growth in both glucose and glycerol liquid medium, there were no
growth defects exhibited by any of the mef2 mutants (Table S1).
Mitochondrial DNA stability was measured periodically for up to
32 generations. The frequency of cells which spontaneously lose
mtDNA amongst populations of each mef2 mutant remained equal
to that of the wild-type (approximately 2 to 3%), verifying that
mtDNA is stable over successive generations.
The five mef2 mutants were then assayed for atorvastatin
sensitivity. Following five days of exposure to 110 mM atorvastatin,
three of the mef2 mutants exhibited a statin hypersensitive
phenotype. Viability of the mef2
I616T, mef2
D578G and mef2
K308R
mutants was reduced to 20.3, 22.8 and 24.2 percent respectively
(Figure 4B). The two other mef2 mutants, mef2
K769Q and
mef2
R740G, did not exhibit a statin sensitive phenotype. The
unmasking of a phenotype for the mef2
K308R, mef2
D578G and
mef2
I616T variants by atorvastatin is a strong indicator that these
mutations have an effect on Mef2p function. A similar effect
conferred by these alleles in the human EF-G2mt protein could
have vital consequences for statin users.
Atorvastatin-sensitive mef2 mutants also have reduced
respiration rates
Although no obvious growth phenotype was observed, the
statin-sensitive phenotype of three of these mutants indicates a
subtle defect in mitochondrial function. Staining of mef2 mutant
cells with the nucleic acid staining dye 49,6-diamidino-2-
phenylindol (DAPI) confirmed the presence of mtDNA nucleoids
in cells of all five mutants and quantification of mtDNA copy
number using quantitative PCR (qPCR) [38] showed that mtDNA
levels were the same as that of the wild-type (Figure S3). It
Figure 2. Growth of siRNA transfected RD cells in glucose and galactose medium. At 24 hours post-transfection, cells were seeded into
wells of a 96-well plate in DMEM medium containing 10% fetal bovine serum and either 4.5 g/L glucose (left panel) or 4.5 g/L galactose (right panel).
Cell proliferation was determined daily using a luminescent cell viability assay. An untransfected cell line and the rho0 cell line were included as
controls. Cell proliferation is shown as a percentage of the maximum cell growth (100%) of the untransfected control. Error bars represent the mean
6 SEM for three independent measurements.
doi:10.1371/journal.pgen.1002755.g002
Table 2. IC50 values for EF-G2mt silenced cells exposed to atorvastatin.
IC50 95% confidence interval P
RD Cells Untransfected control 18.9 16.1 to 22.2
Non-targeting siRNA 18.6 15.7 to 22.0
EF-G2mt targeting siRNA 15.0* 13.8 to 16.4 0.023*
HepG2 Cells Untransfected control 186.9 149.1 to 234.3
Non-targeting siRNA 184.8 148.9 to 228.8
EF-G2mt targeting siRNA 152.4 129.3 to 179.6 0.138
IC50 values of EF-G2mt silenced cells were compared to their respective non-targeting siRNA transfected cell lines using the extra sum-of-squares F-test.
*P,0.05.
doi:10.1371/journal.pgen.1002755.t002
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destabilise Mef2p function so as to compromise mtDNA stability.
To investigate the possibility of a respiratory phenotype, oxygen
consumption for the three statin-sensitive mef2 mutant cultures was
measured (in the absence of atorvastatin) using a non-invasive
oxoluminescent device [35]. All three mutants, mef2
K308R,
mef2
D578G and mef2
I616T, exhibited a significantly reduced respi-
ration capacity, approximately one third lower than that of the
wild-type (Figure 5). The two mef2 mutants that did not display an
atorvastatin-sensitive phenotype had respiration rates much closer
to that of the wild-type. Together, these results demonstrate a
respiratory phenotype conferred by at least three of the EF-G2mt
equivalent mef2 variants and this correlates with the inability of
these mef2 mutants to tolerate atorvastatin toxicity.
Interestingly, the partially respiratory deficient mef2 mutants
exhibit a greater statin sensitivity than the ethidium bromide
generated r
0 strains, which are completely devoid of respiratory
function (Table 1). This, in support of the mef2D results, indicates
the role of a non-respiratory function of MEF2 in the statin
response. In addition to a lack of mtDNA, we have previously
shown, by staining cells with MitoTracker Red CMXRos, that
the mef2D strain has a reduced mitochondrial membrane
potential (DY) and that mitochondria appear fewer, with a
tendency to aggregate [30]. The MitoTracker Red CMXRos
probe enters the mitochondrial matrix dependent on DY.T h i s
same method was used to test DY and mitochondrial morphology
in the mef2 mutants. Cells were visualised using a laser scanning
confocal microscope and, in contrast to the mef2D strain, all five
mef2 mutants displayed mitochondria that stain brightly and are
arranged in a tubular network, typical of mitochondria in wild-
type yeast. Staining of the three partially respiratory deficient
mutants is shown in Figure 6. These results indicate that the mef2
mutations do not disrupt the function of Mef2p in maintaining
DY and so does not explain the enhanced statin sensitivity of
these mutants. It is known that statin toxicity can cause loss of
DY [39]. Therefore one possibility is that atorvastatin acts
synergistically with a mutated Mef2p to exacerbate loss of DY
and compromise cell viability. However, other mechanisms, such
as modulation of the mitochondrial retrograde response, cannot
be discounted [40].
Figure 3. EF-G2mt protein variants. Alignment of the protein amino acid sequence of the human EF-G2mt protein with the yeast Mef2 protein.
Dark shaded areas represent conserved amino acid residues and grey shaded areas represent semi-conserved residues. EF-G2mt SNPs that are
semiconserved in yeast MEF2 are shown in italics and fully conserved SNPs are depicted in bold. The five alleles selected for functional
characterisation are outlined. The five EF-G2mt protein domains are represented below the alignment. Global alignment of protein sequences was
performed using Lalign and the BioEdit sequence alignment editor was used to generate the graphical representation.
doi:10.1371/journal.pgen.1002755.g003
Figure 4. Functional characterisation of EF-G2mt equivalent SNPs in the yeast MEF2 gene. (A) Growth of wild-type, mef2 deletion strain
and mef2 mutants in yeast medium containing either glucose as the carbon source or the non-fermentable carbon source glycerol. Cells from
exponentially growing cultures were serially diluted and 5 ml of each dilution spotted onto each plate. Growth was assessed after 72 hours incubation
at 30uC. (B) Percentage cell viability of yeast mef2 mutants in 110 mM atorvastatin relative to viability of the wild-type strain following exposure to
atorvastatin for 5 days. Data represent mean 6 SEM (n=3). A one-way ANOVA followed by a Dunnett’s multiple comparison test was used to
compare the mean percentage viability of the mef2 variants to that of the wild-type. ***P,0.001.
doi:10.1371/journal.pgen.1002755.g004
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protein predicts function of EF-G2mt protein variants
The crystal structure of the human EF-G2mt protein has not yet
been elucidated. Therefore, to gain insight into the molecular
effects of the five chosen amino acid variations, a computational
model of the EF-G2mt protein was constructed using the SWISS-
MODEL server [41]. The model is based on the experimentally
determined crystal structure of the Thermus. thermophilus EF-G
protein [42] which shares 39 percent identity with the human EF-
G2mt protein and four of the five EF-G2mt protein domains. As
the N-terminal and C-terminal regions of the EF-G2mt protein
share particularly low homology with the template, the initial 65
and final 10 amino acid residues could not be accurately modelled.
For this reason, the location of amino acid variant EF-G2mt
R774Q,
positioned very close to the C-terminus, was omitted (Figure 7A).
Stereochemical quality of the model was assessed by generating a
Ramachandran plot using PROCHECK. Eighty seven percent of
residues fall within the most favoured regions of the plot,
indicating ideal stereochemistry.
Using the in silico model, we can make some hypothetical
predictions about the function of the protein variants. The human
EF-G2mt
K334R variant, which corresponds to the respiratory
compromised yeast mef2
K308R variant, is located on a coil close
to the surface of the GTP-binding domain (domain I) that is highly
conserved in EF-G2mt homologs from all major eukaryotic species.
The presence of GTP is essential for ribosome dissociation at the
termination of translation, and subsequent hydrolysis of GTP is
then required in order to release the EF-G2mt protein from the
ribosome [23]. The EF-G2mt
E594G and EF-G2mt
I627T variants,
equivalent to the respiratory compromised mef2
D578G and
mef2
I616T mutants respectively, are both located in domain IV
and occur close to the EF-G2mt protein surface. The EF-
G2mt
E594G variant is expected to diminish the largely negative
electrostatic surface potential of this domain, thereby interfering in
the protein’s interaction with both the mitochondrial ribosome
and Rrf1 [23,25]. The EF-G2mt
I627T variant is located on an alpha
helix whose structural integrity is disturbed by the threonine
hydroxyl group. The final two EF-G2mt protein variants, in which
the corresponding mef2 mutants did not exhibit a phenotype, are
located in domain V, the C-terminal region that accelerates (but is
not essential for) the ribosome recycling action of the EF-G2mt
protein [23].
In the last year, data from the 1000 Genomes project has
expanded the number of known polymorphisms in the human
genome and a further 11 non-synonymous SNPs have been
discovered within the human EF-G2mt gene (dbSNP, National
Centre for Biotechnology Information (NCBI)) [43]. Of these, one
is fully conserved in the S. cerevisiae Mef2 protein and another five
are semi-conserved (Figure 3 and Figure S2). The location of five
Figure 5. Oxygen consumption rates of mef2 mutant cultures.
Figure depicts the rate of oxygen consumption per minute per 30 mL
of yeast culture at an OD600 of 0.2. Data represent mean 6 SEM (n=3).
A one-way ANOVA followed by a Dunnett’s multiple comparison test
was used to compare the mean oxygen consumption rate of mef2
variants to that of the wild-type. ***P,0.001.
doi:10.1371/journal.pgen.1002755.g005
Figure 6. Visualisation of mitochondrial membrane potential. Cells were stained with MitoTracker Red CMXRos and observed using a laser
scanning confocal microscope. To better visualise mitochondrial structure within the mef2 deletant, cells were stained with a 106concentration of
MitoTracker Red. Scale bar represents 5 mm.
doi:10.1371/journal.pgen.1002755.g006
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PLoS Genetics | www.plosgenetics.org 6 June 2012 | Volume 8 | Issue 6 | e1002755Figure 7. In silico model of the human EF-G2mt protein. (A) Model depicting four of the five amino acid variants that were functionally
characterised in this study. (B) Five newly discovered variants that have yet to be functionally characterised. Helices are shown as ribbons, beta-sheets
are depicted as flat broad arrows and loops and coils appear as thin tubes. The five protein domains of the EF-G2mt protein are distinguished by
different colours. Domain I, the GTP binding domain is shown in blue, domain II is purple, domain III is orange, domain IV is cyan and domain V is
green. Model was visualised using the Visual Molecular Dynamics program (VMD), version 1.8.7 (University of Illinois).
doi:10.1371/journal.pgen.1002755.g007
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Figure 7B. Although experimental confirmation is essential, based
on the findings above it is hypothesised that the domain IV (EF-
G2mt
K621N and EF-G2mt
F609Y) and domain I (EF-G2mt
V165G)
variants will affect protein activity. Therefore, these naturally
occurring EF-G2mt variants may have respiratory deficient
consequences.
Discussion
By exploiting the genetic tractability of yeast, complemented
by siRNA silencing studies in human cell lines, we have identified
a mitochondrial translation factor as a mediator of atorvastatin
toxicity and also made fundamental discoveries about the
function of human variants within the EF-G2mt gene. The
human EF-G2mt gene, ortholog of the yeast MEF2 gene, was
originally identified as a mitochondrial elongation factor gene.
However, a recently published comprehensive analysis of the EF-
G2mt protein has shown that it functions as a ribosome recycling
factor, interacting with the first discovered ribosome recycling
factor protein, Rrf1, to dissociate the ribosomal subunits at the
termination of translation [23]. In yeast, deletion of the MEF2
gene results in loss of mtDNA [30], a circumstance which would
be lethal in higher eukaryotic cells without the supplementation
of uridine and pyruvate [44]. Nevertheless, siRNA silencing
experiments show that in contrast to its RRF1 counterpart,
knockdown of human EF-G2mt expression does not compromise
cell viability in glucose medium. Furthermore, silencing of EF-
G2mt expression does not deplete cellular mtDNA content. It is
possible that some compensatory mechanism enables ribosome
recycling to continue to a sufficient degree to maintain cell
viability in fermentative cell lines.
When galactose is used as the carbon source instead of glucose,
the ATP produced via glycolysis is insufficient for cell energy
requirements; therefore, there is a greater reliance on the
production of ATP through the oxidative metabolism of gluta-
mine. This more closely resembles the metabolic activity of cells in
a human physiological system [37,45]. By using galactose to force
reliance on the mitochondria for cell energy production, it was
shown that reduced EF-G2mt activity does indeed compromise cell
proliferation in respiring cells. It is consequently expected that the
EF-G2mt gene is essential for cell function in a human system.
Furthermore, in support of the notion that abnormalities in
mitochondrial function sensitise cells to statin toxicity, the growth
defect of EF-G2mt silenced cells in galactose medium was even
further exacerbated upon exposure to atorvastatin.
For cells in which mitochondrial function is challenged,
exposure to mitochondrial toxicants, such as statins, places
additional stress on mitochondrial function and this has the
potential to trigger pathogenicity. Indeed we have shown that r
0
strains, lacking respiratory capacity, are more sensitive to
atorvastatin than those with a functioning mitochondrial genome
in both yeast and human cells. Studies have shown that statins
exert their mitochondrial toxicity effects by inhibiting function of
the electron transport chain but there is also evidence of non-
respiratory mitochondrial consequences [46,47,48]. These include
a loss of mitochondrial membrane potential, aberrant mitochon-
drial morphology and apoptosis [39]. These effects, in combina-
tion with the absence of respiratory function may explain the
hypersensitivity of r
0 cells to statin.
The hypersensitivity of respiratory deficient cells to statins may
have clinical ramifications for patients that have variations within
mitochondrial functioning genes. Statins have been known to
aggravate clinically silent disease associated mutations resulting in
myopathies. In fact, mutations (which in many cases were
asymptomatic) for three common myopathic diseases; carnitine
palmitoyltransferase II deficiency, McArdle disease and myoade-
nylate deaminase deficiency (AMPD deficiency), are thought to be
the underlying determinants responsible for statin-induced myop-
athy in up to 10 percent of patients showing adverse effects [5].
There are also reports of the statin-induced triggering of MELAS
syndrome in patients whose MELAS mutations were clinically
silent [13,14]. As MELAS syndrome arises from mutations in
mtDNA, it strongly implicates mitochondrial dysfunction in
susceptibility to statin toxicity. This is further supported by the
identification of two commonly occurring SNPs in the human
COQ2 gene that are associated with an increased risk of statin
intolerance [49]. The COQ2 gene is required for the synthesis of
coenzyme Q10, an essential component of the mitochondrial
electron transport chain [49].
Despite the presence of a number of SNPs within the EF-G2mt
gene, the function of these variants for cell fitness had never been
investigated. In this study, five EF-G2mt equivalent SNPs were
selected for functional analysis in the yeast MEF2 gene. Unlike the
mef2D deletant, all mef2 mutants grew proficiently on both glucose
and the non-fermentable carbon source glycerol. Furthermore, the
mutations had no effect on mtDNA stability, DY or mitochondrial
morphology. However, exposure of the mutants to toxic concen-
trations of atorvastatin has uncovered a phenotype for three of the
mef2 mutants; mef2
K308R, mef2
D578G and mef2
I616T, equivalent to
the EF-G2mt
K334R, EF-G2mt
E594G and EF-G2mt
I627T alleles
respectively. In silico protein homology modelling reveals these
three mutations are located in either the GTP binding domain
(domain I) of the EF-G2mt protein or an external domain (domain
IV) necessary for ribosomal interaction.
Based on the observations that statins exacerbate clinically silent
disease associated mutations, it was predicted that the three
mutations compromise mitochondrial function in a subtle yet
potentially significant way. The subsequent observation that
oxygen consumption was significantly reduced in the statin-
sensitive mef2 mutants confirmed this hypothesis and demonstrates
a sub-optimal mitochondrial function for the three EF-G2mt
equivalent mef2 mutants. This sub-optimal mitochondrial function
is expected to contribute to the atorvastatin-sensitive phenotype of
the three mef2 mutants. However, comparison of the statin
sensitive phenotype of the mef2
K308R, mef2
D578G, mef2
I616T and
mef2D mutants with cytoplasmic r
0 strains indicates that statin
sensitivity is not fully explained by the reduced respiratory capacity
of these mutants and further studies are required to completely
elucidate the precise mechanism.
This study constitutes the first report of a phenotype associated
with EF-G2mt, demonstrating an essential role for aerobic
respiration in human cell lines and an importance for cell
tolerance to atorvastatin. Atorvastatin constituted the focus of this
study and is the highest selling and also one of the more potent of
the statins [50]. Although the various statins have been shown to
differ in their cellular toxicity effects, all of them have been
implicated with mitochondrial dysfunction [48,50,51,52,53]. It
would therefore be expected that a mitochondrial mediator of
atorvastatin toxicity may also mediate cell response to the other
statins. In support of this, preliminary experiments confirm that
the atorvastatin sensitive mef2 mutants also exhibit sensitivity to
lovastatin.
With an estimated 38 million people around the world
undertaking statin treatment [9], the identification of novel
biomarkers for statin toxicity has the potential to personalise
therapy for millions of individuals. To date, only a handful of
genes have been associated with statin toxicity [9], but the finding
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strengthened the association between existing mitochondrial
dysfunction and statin hypersensitivity. Importantly, the discovery
of naturally occurring human polymorphisms within the EF-G2mt
gene that affect respiratory function indicates that these variants,
either alone or in combination with other polymorphisms, have
significant pathogenic consequences. This opens avenues for
further clinical investigations into a possible association between
EF-G2mt variants and disease.
Materials and Methods
Chemicals
Atorvastatin calcium was purchased from 7 Chemicals (India).
Stock solutions were prepared by dissolving atorvastatin in
methanol at a concentration of 20 mg/mL and solutions were
stored at 220uC. 5-fluoroorotic acid and geneticin (G418) were
purchased from Sigma.
Yeast strains and media
The haploid wild-type S. cerevisiae strains used were of the
background BY4741 (MATa his3D1 leu2D0 met15D0 ura3D0) and
BY4742 (MATa his3D1 leu2D0 lys2D0 ura3D0). The diploid strain
was BY4743 (MATa/a his3D1/his3D1 leu2D0/leu2D0 LYS2/lys2D0
MET15/met15D0 ura3D0/ura3D0) [54]. The mef2D/MEF2, mef2D
and the cytoplasmic r
0 strains were previously described [30].
Prior to experiments, yeast strains were cultured in liquid YEPD
(1% yeast extract, 2% peptone, 2% dextrose) medium for
24 hours, subcultured and then grown to exponential phase in
Synthetic Complete (SC) medium (0.67% Difco yeast nitrogen
base without amino acids, 2% dextrose, 0.79 g L
21 amino acid
supplement (Sunrise Science Products, Australia)). Cells were
incubated at 30uC with shaking.
Statin viability assay in yeast
Triplicate exponential phase cultures grown in SC medium
were diluted to an optical density (OD595 nm) of 0.2 and 1.25 mL
of this culture was added to 3.75 mL SC medium with the
appropriate concentration of atorvastatin. After a maximum of
five days growth, cells were diluted and plated onto solid YEPD
(YEPD plus 2% agar) medium and viability counts were
performed 48 hours later.
Cell culture
HepG2 cells and RD Cells are from the American Type Culture
Collection (ATCC). Cells were cultured at 37uC and 5% CO2 in
Dulbecco’s Modified Eagle’s Medium (DMEM) medium (Gibco)
containing 4.5 g/L glucose and 10% fetal bovine serum (FBS)
(Bovogen Biologicals, Australia). For experiments in which
galactose was used as the carbon source, cells were grown in
glucose free DMEM with 10% fetal bovine serum and 4.5 g/L
galactose. To generate the r
0 cell lines, used as respiratory
deficient controls, HepG2 and RD cells were cultured for eight
weeks in DMEM medium containing 100 ng/mL ethidium
bromide and supplemented with 10% FBS, 50 mg/mL uridine
and 100 mg/mL sodium pyruvate [31,44]. Following ethidium
bromide treatment, r
0 cells were maintained in medium
supplemented with uridine and sodium pyruvate. Depletion of
mtDNA was confirmed using qPCR.
Cell transfection with siRNA
The ON-TARGETplus SMARTpool, comprising of four
siRNAs targeting the EF-G2MT transcript (NM_170691) was
purchased from Dharmacon (cat. # L-017534-01-0005, Dharma-
con, Thermo Fisher Scientific, Lafayette, CO.). The correspond-
ing ON-TARGETplus non-targeting SMARTpool (cat. #D-
001810-10-05) and DharmaFECT transfection agents were also
purchased from Dharmacon. DharmaFECT agent 2 (0.2 mL/
100 mL) and DharmaFECT agent 4 (0.4 mL/100 mL) were used to
transfect RD cells and HepG2 cells respectively. All siRNAs were
used at a final concentration of 25 nM. To transfect cells, equal
volumes of the siRNA and transfection agent were mixed, allowed
to incubate for 30 minutes, and 100 mL of the solution was added
to 400 mL DMEM medium containing 10% FBS. This solution
was added to the attached cells which had been washed in PBS.
Gene expression silencing was assessed at 72 hours post-transfec-
tion by qPCR. For experiments in which cells were re-transfected,
the above procedure was performed again at 72 hours subsequent
to the initial transfection.
Cell proliferation assay
At 24 hours post-transfection, approximately 1610
4 cells/well
of each culture were seeded into eight wells (one for each day of
the eight-day proliferation assay) of a 96-well plate and allowed to
attach overnight. Each day, the number of viable cells in one of the
eight wells was assessed using the CellTiter-Glo assay (Promega) as
described above. Cell medium was changed every two days.
IC50 assays
Approximately 5610
4 cells/well were seeded into wells of a 96-
well plate. For siRNA transfected cells, seeding occurred at
24 hours post-transfection. Following overnight incubation to
enable attachment, media was changed to DMEM containing
10% FBS plus the appropriate atorvastatin concentration.
Atorvastatin concentrations ranged from 0 to 128 mM for RD
cells and 0 to 1024 mM for HepG2 cells. Cell survival after
48 hours in the presence of atorvastatin was estimated using the
CellTiter-Glo luminescent cell viability assay (Promega), which
measures intracellular ATP concentration. The assay was
performed according to the manufacturer’s instructions and
luminescence was quantified using a Tecan Genios microplate
reader. IC50 values were calculated from dose-response curves that
were generated using least-squares linear regression.
Construction of SNP mutations in yeast MEF2 gene
Codon modifications used to alter yeast Mef2p amino acid
residues to those of the corresponding EF-G2mt variants are
A2305C, A2219G, T1848C, A1734G and A924G for the yeast
mef2
K769Q, mef2
R740G, mef2
I616T, mef2
D578G and mef2
K308R respec-
tively. The GenBank accession number for the MEF2 sequence
used was NC_001142.9. The single base pair substitutions were
created in the yeast MEF2 gene according to the double-strand
break mediated delitto perfetto method [55]. The pGSKU plasmid
containing the CORE-I-SceI cassette was kindly provided by
Francesca Storici (Georgia Tech, Atlanta, GA). The CORE-I-SceI
cassette was PCR amplified with chimeric primers (Table S2) that
contain 50 bp homologous to the site of insertion and 20 bp for
amplification of the cassette. Cassette amplification was performed
in 50 mL PCR reactions (25 mL2 6 Phusion Flash PCR Master
mix (Finnzymes), 0.5 mM each primer and approximately 1–10 ng
purified pGSKU plasmid) using a PTC-200 thermal cycler (MJ
Research) (Initial denaturation, 98uC for 10 seconds; denature,
98uC for 1 second; anneal/extend, 72uC for 75 seconds; repeat
denature and anneal/extend for 30 cycles; final extension, 72uC
for 1 min). Cells were transformed with 10 mL of the concentrated
PCR product as previously described [55]. Transformants were
selected by plating onto synthetic medium lacking uracil (0.67%
Difco yeast nitrogen base without amino acids, 2% dextrose,
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21 uracil dropout amino acid supplement (Sunrise
Science Products, Australia) and 2% agar) and after 24 hours,
G418 resistance was checked by replica plating onto solid YEPD
containing 200 mg/mL G418 (Sigma). Colony PCR was per-
formed to confirm accurate integration of the cassette. Cells
containing the integrated CORE-I-SceIc a s s e t t ew e r et h e n
transformed with 0.5 nM of each strand of a pair of comple-
mentary 80 bp oligonucleotides (Table S2) containing the desired
substitution and possessing 40 bp on either side of the oligo which
is targeted to the regions adjacent to the integrated marker
(GeneWorks, Adelaide). To induce the I-SceI mediated double
strand break at the recombination site, prior to transformation
cells were cultured in 50 mL of synthetic complete medium
containing 2% galactose instead of glucose and incubated at 30uC
with shaking for a period of six to eight hours. Following
transformation, cells were plated onto solid YEPD medium and
after 24 hours, replica plated onto synthetic complete medium
containing 1 g/L 5-fluoroorotic acid and 60 mg/L uracil to
check for loss of the URA3 marker. Loss of the CORE-I-SceI
cassette was confirmed using colony PCR (primers listed in Table
S2) and the resulting PCR product was sequenced to ensure the
desired mutation was present. Due to complete disruption of the
MEF2 gene during insertion of the cassette, all resulting mef2
mutants were lacking mtDNA. Therefore, to reintroduce
mtDNA, mutant strains were mated with the wild-type of
opposite mating type (the BY4741 strain (MATa)). Diploid strains
were then sporulated and dissected, resulting in 2:2 segregation of
wild-type and mef2 mutant colonies, all of which were r
+.
Sequencing was used to identify the colonies which possessed the
desired mutation.
Measurements of oxygen utilisation
Cell respiration was measured by monitoring dissolved oxygen
levels in 30 mL of exponential phase yeast cells at an optical
density of 0.2 in YEPD medium. Cells were cultured in 50 mL
Erlenmeyer flasks sealed with a rubber bung to minimise the
exchange of oxygen with the external environment. Each flask was
equipped with a PreSens PSt3 oxygen sensitive spot (NomaCorc)
and the percentage of dissolved oxygen in the medium was
measured using an oxoluminescent device, the NOMASense
oxygen analyser system (NomaCorc) [35], every 15 minutes until
percent oxygen reached below 10% for the wild-type strain.
Visualisation of mitochondrial membrane potential (DY)
MitoTracker Red CMXRos (Molecular Probes) was added
directly to a 500 mL volume of exponential phase culture in YEPD
to a final concentration of 250 nM (16) or 2500 nM (106). Cells
were incubated at 30uC for 30 minutes, washed with fresh
medium and resuspended in YEPD medium. Cells were mounted
onto a glass slide and viewed immediately using a laser scanning
confocal microscope (Zeiss LSM 710, Carl Zeiss Microimaging,
Germany) controlled using the ZEN 2010 software (Carl Zeiss
Microimaging, Germany). The excitation line used was 543 nm
and the laser power was set at 2%. Cells were viewed using 6306
optical magnification and 36 digital magnification. All samples
were analysed using the same settings.
Protein homology modelling
The protein model of the human EF-G2mt protein was based on
thecrystalstructure of the Thermus thermophilusEF-G protein(Protein
Data Bank 2bm0) [42]. This shares 39% residue identity. Selection
of the T. thermophilus template and homology modelling was carried
out using the SWISS-MODEL server in ‘project mode’ to enable
alignment inspection prior to modelling [41]. The completed model
was then submitted to the SWISS-MODEL suite of quality check
programs which tests for model quality and stereochemistry using
algorithms such as ANOLEA [56] and PROCHECK [57]. The
modelwasvisualisedusingtheVisualMolecularDynamicsprogram
(VMD), version 1.8.7 (University of Illinois) and this software was
also used for the assignment of protein secondary structure and the
assessment of electrostatic potential.
Bioinformatics
All sequences, both yeast and human, were obtained from the
Ensembl database. There are three known human EF-G2mt
protein isoforms but isoform I (AAH15712.1) was used throughout
this study. Human EF-G2mt SNPs were identified using the dbSNP
database available on the National Center for Biotechnology
Information (NCBI) website (www.ncbi.nlm.nih.gov/SNP/index.
html). The Lalign program available on the Swiss EMBnet server
(www.ch.embnet.org/software/lalign_form.html) was used to gen-
erate global alignments of protein sequences, based on the
BLOSUM50 matrix [58]. Graphical representations were con-
structed using the BioEdit version 7.0.5 sequence alignment editor.
Supporting Information
Figure S1 Quantitative PCR analysis of mtDNA levels for EF-
G2mt siRNA transfected RD cells relative to the non-targeting
siRNA control. The mtDNA/nDNA ratio was determined using
qPCR at 72 hours post-transfection. Cells were re-transfected
and mtDNA was analysed again following another 72 hours.
The nuclear r18S gene and the mitochondrial ND1 gene were
used to determine the quantity of nuclear DNA and mtDNA
respectively.
(TIF)
Figure S2 Global protein alignment of human EF-G2mt and
yeast Mef2p. Red shaded boxes along the EF-G2mt protein
sequence indicate amino acid variations resulting from non-
synonymous SNPs in the human EF-G2mt gene. A corresponding
red shaded box in the yeast Mef2p alignment designates a fully
conserved amino acid residue and a blue shaded box represents a
semi-conserved residue.
(PDF)
Figure S3 Quantitative PCR analysis of mtDNA levels of the
yeast mef2 mutants relative to the wild-type. The mtDNA/nDNA
ratio was determined using qPCR. There was no detection of
mtDNA in the r
0 mef2D deletion mutant, denoted ND. Data
represents the mean 6 SEM (n=3). The nuclear ACT1 gene and
the mitochondrial COX1 gene were used to determine the quantity
of nuclear DNA and mtDNA respectively.
(TIF)
Table S1 Growth rate of mef2 mutants in glucose and glycerol
medium. Triplicate exponential phase cultures were diluted to an
optical density (OD595 nm) of 0.2 and 50 ml of this culture added to
150 ml of YEPD in wells of a 96-well plate. Cell growth was
monitored by measuring OD at 595 nm every hour for 15 hours
in a Tecan Genios microplate reader. Cell doubling time was
calculated using the formula ln 2/k, where k is the maximal slope
of the curve when ln(OD595) is plotted against time. Data represent
the mean cell doubling time 6 SEM (n=3). A one-way ANOVA
was used to compare mean cell doubling time of mutants with that
of the wild-type. ***P,0.001.
(PDF)
Table S2 Oligonucleotides used in this study.
(PDF)
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